NEW YORK (GenomeWeb News) – Celera today said that it has licensed exclusive worldwide rights to Bayer Schering Pharma for five cancer-related drug targets and associated in vivo diagnostic imaging.

The Alameda, Calif.-based molecular diagnostics firm said that it will retain in vitro diagnostic rights and will be able to develop and sell companion diagnostics specific to therapeutic compounds developed by Bayer under the deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.